Bank of America upgraded shares of Galapagos (NASDAQ:GLPG) from an underperform rating to a neutral rating in a research report sent to investors on Tuesday morning, Briefing.com reports. Bank of America currently has $94.00 price target on the biotechnology company’s stock, up from their prior price target of $93.00.
Other research analysts also recently issued reports about the company. Zacks Investment Research upgraded Galapagos from a sell rating to a hold rating in a research note on Tuesday, November 24th. TheStreet cut Galapagos from a c- rating to a d+ rating in a report on Monday, December 7th. Morgan Stanley raised Galapagos from an equal weight rating to an overweight rating in a report on Tuesday, January 19th. Maxim Group cut Galapagos from a buy rating to a hold rating in a report on Wednesday, February 10th. Finally, UBS Group reaffirmed a neutral rating on shares of Galapagos in a report on Thursday, February 11th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $177.00.
Shares of GLPG stock opened at $85.69 on Tuesday. The business’s 50 day moving average is $100.33 and its two-hundred day moving average is $123.18. Galapagos has a twelve month low of $81.89 and a twelve month high of $252.31. The company has a market capitalization of $5.61 billion, a P/E ratio of -12.98 and a beta of 0.76.
Galapagos Company Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, SjÃ¶gren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis.
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.